Plain-English translation of NCT07095790 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether tirofiban, a medication that helps prevent blood clots, combined with standard antiplatelet drugs, can help people recover better after a mild stroke. Right now, doctors typically use dual antiplatelet therapy alone (two blood-thinning pills) for mild stroke, but some patients still experience worsening symptoms or poor recovery. This study compares the new treatment approach to the current standard to see if it leads to better outcomes.
Even with current standard treatment, mild stroke patients sometimes get worse in the days after their stroke or don't recover as well as hoped. This medication has shown promise in other stroke studies, but doctors need solid evidence to know whether it truly helps mild stroke patients do better than they would with standard care alone.
You likely qualify if…
You likely don't qualify if…
If you qualify and join this study, you will be randomly assigned to one of two groups. One group will receive tirofiban through an IV for 48 hours starting within 48 hours of their stroke, then switch to two antiplatelet pills. The other group will receive only the two antiplatelet pills from the start. You will be followed up with visits and assessments to measure how well you recover over time and whether either approach leads to better outcomes.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
China